Veno-arterial extracorporeal membrane oxygenation support for cardiogenic shock secondary to immune checkpoint inhibitors
Published online on July 29, 2025
Abstract
Perfusion, Volume 41, Issue 4, Page 490-493, May 2026.
IntroductionTremelimumab in combination with Durvalumab has recently been approved for the treatment of unresectable hepatocellular carcinoma (HCC). While immune checkpoint inhibitors (ICIs) have transformed cancer therapy, they are associated with rare ...
IntroductionTremelimumab in combination with Durvalumab has recently been approved for the treatment of unresectable hepatocellular carcinoma (HCC). While immune checkpoint inhibitors (ICIs) have transformed cancer therapy, they are associated with rare ...